Piramals are the largest investors in the Indian real estate sector after HDFC, with investments worth $3 billion already.
Nicholas Piramal has signed an MoU with a French pharma company to manufacture an anti-chikungunya drug.
Pharma major Nicholas Piramal India Ltd will develop and commercialise a select group of US-based Eli Lilly and Company's pre-clinical drug products that span multiple therapeutic areas.
'Professors can teach even when they are 90 because they don't lose their skill with words. Go deeper and there's spirituality in it.'
Nicholas Piramal India Ltd said on Thursday its UK subsidiary has entered into an agreement to acquire the manufacturing facility of global pharma company Pfizer Inc at Morpeth, UK, on an asset purchase basis.
Pharmaceutical major Nicholas Piramal India Ltd on Monday said the company was looking for acquisition in United Kingdom and North America to expand its overseas operation.
Bhatt, president (Manufacturing) of the Company's Pithampur plant, reached Indore on Sunday morning after being rescued from a makeshift mud hut from Natua Ka Pura ravines of Chambal area in Morena district on Satuday night. He was abducted by armed persons when he was returning home to Indore from Gwalior, in his Toyota Corolla, on January 18.
Senior executive of pharma major Nicholas Piramal Ashwini Bhatt and his driver, who were kidnapped on January 18, were traced by the Special Task Force of Madhya Pradesh Police along MP-UP border on Saturday.
Nicholas Piramal India Ltd has bought out the balance 50 per cent stake in Sarabhai Piramal Pharmaceuticals Ltd from Ambalal Sarabhai Enterprises (ASE) for Rs 69.3 crore (Rs 693 million) in an all cash deal to consolidate its presence in pharmaceutic
Nicholas Piramal India has acquired UK-based Avecia Pharmaceuticals for £9.5 million.
Piramal Realty received equity funding from Warburg Pincus and Goldman Sachs in July.
Nicholas Piramal India Ltd said Bombay High Court approved its merger with Global Bulk Drugs & Fine Chemicals Pvt Ltd.
Even after investing almost Rs 6,000 crore, Ajay Piramal, chairman of the company, insists it is a short-term investment.
Their engagement party was held at Lake Como, Italy.
Starlight Systems, a unit of Piramal Sunteck Realty, has sought a four-year staggered payment option to pay Rs 496 crore (Rs 4.96 billion) for two plots it won in the financial district of Mumbai in the last financial year.
His strategy of acquiring cheap assets and selling at high valuations may not have impressed shareholders, but after the mega deal with Vodafone peers are quick to compare him with the Oracle of Omaha.
The list of guests included celebrities from across the globe, politicians, the who's who of Hindi and south Indian cinema world and almost all the top cricketers of the country.
NPIL had announced that it would team up with the French company to develop a drug for the epidemic about six months ago, following the spread of the disease, mainly in southern India and Maharashtra in the last two years. Currently, drugs are not available to effectively treat the disease and doctors in the country administer viral disease drugs such as paracetamol and other anti-biotics to check the infection.
Suuti's merchant bankers give proposal; deal value could be Rs 2,800 crore
Future Gaming and Hotel Services whose director is the lottery magnate Santiago Martin is the top purchaser of electoral bonds having purchased bonds worth Rs 1,368, according to data uploaded by the Election Commission of India on its website on Thursday.
'There is not any negative connotation associated with it.'
Drug firm Piramal Healthcare on Tuesday said it will acquire assets of troubled Canadian medical device firm BioSyntech for Canadian $3.9 million (around Rs 17 crore).
Which entrepreneur would willingly part with her or his hard-earned money for grasping, self-serving politicians? asks Debashis Basu.
Piramal Healthcare is planning a string of acquisitions in the biotech space in the US, Europe and Canada in the next two to three years.
While about 8,000 people are in the long list of invitees, the select list features 506 A-listers, including prominent politicians, leading industrialists, top film stars, sportspersons, diplomats, judges and high priests.
In order to fund potential acquisitions, Nicholas Piramal India Ltd will raise $1.5 billion through issue of securities in domestic and international markets.
The cash-rich Piramal Healthcare has closed its second deal in the past month to strengthen its pharma research and development business. The company has said it would acquire the US-based Decision Resources Group (DRG) for a consideration of nearly $635 million (Rs 3,400 crore).
Pharma major Nicholas Piramal India Ltd has claimed to have developed a novel anti-cancer drug to arrest and regulate the multiplication of cancer cells.
It also asked why the data shared pertained to a period from April 2019 even though the scheme for anonymous political funding was introduced in 2017.
Investors have stepped up ploughing money into the healthcare sector in India.
Drug firm Nicholas Piramal India Ltd said on Thursday it plans to invest about $50 million (about Rs 2.25 billion) in the next two years for developing and manufacturing formulations in the UK and India.
The Mumbai-based Piramal Healthcare is preparing to become the first private sector company to process opium for use in pharmaceutical products.
From steel tycoon Lakshmi Mittal to billionaire Sunil Bharti Mittal's Airtel, Anil Agarwal's Vedanta, ITC, Mahindra and Mahindra, and a lesser-known Future Gaming and Hotel Services were among the prominent buyers of the now-scrapped electoral bonds for making political donations.
Alternative investment funds (AIFs) have not seen any significant redemptions from financial institutions even though the 30-day timeline provided by the Reserve Bank of India (RBI) to liquidate their holdings or make full provisions ends recently. Sources said the industry is awaiting certain relaxations or extensions based on the recommendations submitted to the banking regulator. On December 19, the RBI restricted financial institutions and banks from investing in AIFs where there is any downstream link or exposure to a debtor firm.
Tata Sons chairman Natarajan Chandrasekaran was paid Rs. 113 crore as remuneration for 2022-23 (FY23), including Rs. 100 crore as commission on profit. Chandrasekaran, 60, often referred to as Chandra, received a remuneration of Rs. 109 crore in 2021-22 (FY22). With this, Chandra has emerged as one of the highest-paid chief executive officers (CEO) in Corporate India for FY23.
© 2026 Rediff.com - Investor Information - Advertise with us - Disclaimer - Privacy Policy - Sitemap - Feedback - About us - Terms of use - Grievances